This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tenenbaum, S. Articles by Green, L. Search for Related Content PubMed Articles by Tenenbaum, S. Articles by Green, L. Social Bookmarking                   What's this?

An experimental comparison of Pycnogenol® and methylphenidate in adults with Attention-Deficit/ Hyperactivity Disorder (ADHD)

J.C. Paull

E.P. Sparrow

D.K. Dodd

L. Green

Twenty-four adults (24 to 53 years old) with Attention-Deficit/Hyperactivity Disorder (ADHD), Combined Type, were studied in a double-blind, placebo-controlled, crossover study of Pycnogenol® and methylphenidate. Pycnogenol is an antioxidant derived from the bark of the French maritime pine tree. Methylphenidate is a standard pharmaceutical intervention for ADHD. Anecdotal reports suggest that Pycnogenol improves concentration in adults with ADHD without adverse side effects.

Participants received Pycnogenol, methylphenidate, and placebo, each for 3 weeks, in a randomized and counterbalanced order. Although ADHD symptoms improved during treatment, neither methylphenidate nor Pycnogenol outperformed the placebo control, as measured by self-report rating scales, rating scales completed by the individual's significant other, and a computerized continuous performance test. The conservative dosage levels and relatively brief length of treatment may have contributed to the absence of significant differences among treatment conditions. Implications for future research are noted.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?